Nuvalent Inc (NUVL)
Official siteBIOTECHNOLOGY
Last updated: Jul 16, 2026 at 5:00 PM ET
Nuvalent Inc (NUVL) Financials: Revenue, Profit and Cash Flow
Nuvalent reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$425.38M, operating cash flow was -$275.21M and free cash flow was -$275.21M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$109.28M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $414.31M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $306.97M | $217.77M | $113.24M | $63.73M | $35.56M | $15.40M | $9.75M |
| Operating income | -$414.31M | -$280.37M | -$149.49M | -$86.11M | -$45.82M | -$16.91M | -$10.36M |
| Net income | -$425.38M | -$260.76M | -$126.22M | -$81.85M | -$46.34M | -$14.56M | -$11.81M |
| EBITDA | N/A | N/A | -$136.33M | -$82.23M | N/A | -$14.56M | N/A |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$119.41M | -$102.23M | -$112.70M | -$104.57M | -$94.81M | -$86.30M | -$76.33M | -$65.15M | -$52.59M | -$46.44M | -$38.78M | -$34.06M |
| Net income | -$109.28M | -$118.70M | -$122.44M | -$99.65M | -$84.58M | -$74.76M | -$84.34M | -$57.17M | -$44.48M | -$38.29M | -$33.65M | -$29.09M |
Balance Sheet
As of Dec 2025, cash and equivalents of $261.75M were 18.6% of total assets of $1.41B, against total liabilities of $164.37M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $1.41B | $1.14B | $732.38M | $482.46M | $293.82M | $10.65M | $3.32M |
| Current assets | $1.39B | $1.13B | $726.49M | $477.99M | $290.63M | $10.65M | $3.32M |
| Cash and equivalents | $261.75M | $145.69M | $335.39M | $241.81M | $68.53M | $10.33M | $3.02M |
| Total liabilities | $164.37M | $71.96M | $31.82M | $19.48M | $8.79M | $6.62M | $20.57M |
| Short-term debt | N/A | N/A | N/A | N/A | N/A | $1.96M | $3.15M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $2.23M | $2.17M |
| Shareholder equity | $1.25B | $1.07B | $700.56M | $462.98M | $285.04M | -$31.32M | -$17.26M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.33B | $1.41B | $979.91M | $1.04B | $1.11B | $1.14B | $1.19B | $675.23M | $708.47M | $732.38M | $425.08M | $441.95M |
| Total liabilities | $156.78M | $164.37M | $134.51M | $100.80M | $94.75M | $71.96M | $67.73M | $38.19M | $33.43M | $31.82M | $29.10M | $20.80M |
| Cash and equivalents | $159.73M | $261.75M | $115.75M | $127.47M | $120.83M | $145.69M | $369.24M | $77.70M | $98.52M | $335.39M | $88.43M | $70.87M |
| Shareholder equity | $1.17B | $1.25B | $845.40M | $939.74M | $1.01B | $1.07B | $1.12B | $637.04M | $675.04M | $700.56M | $395.98M | $421.15M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$275.21M | -$185.06M | -$99.74M | -$64.97M | -$40.00M | -$14.95M | -$9.64M |
| Free cash flow | -$275.21M | -$185.06M | -$99.74M | -$64.97M | -$40.00M | -$14.95M | -$9.64M |
| Share repurchases | $382.00K | $483.00K | $856.00K | $644.00K | $3.02M | $0 | N/A |
| Investing cash flow | -$124.08M | -$573.51M | -$143.53M | -$10.66M | -$220.03M | $0 | -$220.03M |
| Financing cash flow | $515.34M | $568.88M | $336.85M | $248.92M | $318.22M | $22.27M | $22.27M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$92.40M | -$73.33M | -$70.46M | -$76.60M | -$54.82M | -$62.00M | -$45.82M | -$41.16M | -$36.09M | -$30.21M | -$22.98M | -$22.14M |
| Free cash flow | -$92.40M | -$73.33M | -$70.46M | -$76.60M | -$54.82M | -$62.00M | -$45.82M | -$41.16M | -$36.09M | -$30.21M | -$22.98M | -$22.14M |
Frequently Asked Questions About NUVL
What is Nuvalent's annual revenue?
Nuvalent reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Nuvalent profitable?
No. Nuvalent reported net income of -$425.38M for the fiscal year ended Dec 31, 2025.
How much free cash flow does NUVL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$275.21M minus capital expenditures of $0 produced free cash flow of -$275.21M.
How much debt does Nuvalent have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $261.75M.
NUVL pages: Overview, Financials